STERIS (NYSE:STE) Sets New 1-Year High – What’s Next?

STERIS plc (NYSE:STE)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $268.60 and last traded at $267.5980, with a volume of 557758 shares. The stock had previously closed at $263.08.

Analysts Set New Price Targets

Several brokerages have recently issued reports on STE. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Finally, Morgan Stanley increased their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Trading Up 1.7%

The company’s fifty day moving average price is $247.21 and its 200-day moving average price is $241.92. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The stock has a market cap of $26.26 billion, a price-to-earnings ratio of 40.98 and a beta of 1.02.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating the consensus estimate of $2.38 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same period in the prior year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, research analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.9%. STERIS’s dividend payout ratio is currently 36.21%.

Insider Transactions at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 25,203 shares of company stock valued at $6,624,667. Corporate insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

A number of hedge funds have recently added to or reduced their stakes in STE. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of STERIS in the third quarter valued at about $25,000. Cloud Capital Management LLC acquired a new stake in STERIS during the 3rd quarter valued at $29,000. Spurstone Advisory Services LLC purchased a new position in shares of STERIS during the 2nd quarter valued at approximately $29,000. Geneos Wealth Management Inc. raised its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new stake in STERIS during the third quarter worth about $37,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.